LUMIRACOXIB CAS: 220991-20-8

CAS NO: 220991-20-8
LUMIRACOXIB
Chemical Name: LUMIRACOXIB
Molecular Formula: C15H13ClFNO2
Formula Weight: 293.72
CAS No.: 220991-20-8
Description Review
Description

Lumiracoxib is a medication used to treat pain and inflammation associated with various conditions, including osteoarthritis and acute pain. The chemical name for Lumiracoxib is 2-[[[4-(methylsulfonyl)phenyl]amino]carbonyl]-5-methoxyphenyl acetic acid. It has the molecular formula C19H18N2O4S and a formula weight of 362.42 g/mol. The CAS number for Lumiracoxib is 220991-20-8.

Top ten keywords from Google and Synonyms:

  1. Lumiracoxib mechanism of action
  2. Lumiracoxib side effects
  3. Lumiracoxib dosage
  4. COX-2 inhibitor
  5. Nonsteroidal anti-inflammatory drug (NSAID)
  6. Osteoarthritis medication
  7. Acute pain relief
  8. Prexige
  9. Anti-inflammatory medication
  10. Prostaglandin synthesis

Health benefits of this product: Lumiracoxib is primarily used to treat pain and inflammation associated with various conditions, such as osteoarthritis and acute pain. This medication works by blocking the action of cyclooxygenase-2 (COX-2), an enzyme that plays a role in inflammation and pain. By doing so, Lumiracoxib can improve symptoms such as pain, swelling, and stiffness in affected joints or areas of the body.

Potential effects: The potential effects of Lumiracoxib can vary depending on the individual patient's condition and response to treatment. In general, this medication has been shown to be effective at reducing pain and inflammation associated with osteoarthritis and acute pain. Lumiracoxib can also improve overall quality of life and well-being in patients with these conditions.

Product mechanism: Lumiracoxib belongs to a class of medications known as nonsteroidal anti-inflammatory drugs (NSAIDs), specifically selective COX-2 inhibitors. These medications work by blocking the action of COX-2, an enzyme that plays a role in inflammation and pain. By doing so, Lumiracoxib can reduce the production of prostaglandins, molecules that promote pain and inflammation in the body.

Safety: Like all medications, Lumiracoxib can cause side effects, some of which can be severe or life-threatening. It is important to discuss any concerns or questions with a healthcare provider before starting this medication. Additionally, patients who take Lumiracoxib may need to have regular monitoring of their liver function and other vital signs to ensure that they are within normal limits.

Side effects: The most common side effects of Lumiracoxib include headache, nausea, and abdominal pain. Other potential side effects include high blood pressure, fluid retention, and an increased risk of heart attack or stroke. Some patients may also experience more serious side effects, such as liver damage or allergic reactions. If any side effects occur, it is important to notify a healthcare provider right away.

Dosing information: The recommended dose of Lumiracoxib varies depending on the individual patient's condition and response to treatment. It is important to follow the dosing instructions provided by a healthcare provider and not exceed the recommended dose. Lumiracoxib should be taken with food to help minimize stomach upset.

Conclusion: Lumiracoxib is an effective medication used to treat pain and inflammation associated with various conditions, such as osteoarthritis and acute pain. This medication works by blocking the action of COX-2, an enzyme that plays a role in inflammation and pain. While generally considered safe, there are potential side effects associated with its use, and it is important to discuss any concerns with a healthcare provider. Overall, Lumiracoxib is an important medication for people with pain and inflammation that can improve quality of life and overall well-being

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code